Stanewick Gerald T

Avg. Two Year Performance

(38%) Avg. Purchase Return
(18%) Compound
39% Avg. Sale Return
18% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return< 1%(10%)(17%)(12%)(38%)
Purchase Success Rate5 of 72 of 72 of 72 of 73 of 7
Average Sale Return(11%)7%11%23%39%
Sale Success Rate1 of 32 of 32 of 32 of 32 of 3

Adhera Therapeutics, Inc.

Drugs » Biotechnology

Director:

Holdings: 175.41K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--